next generation tools enabling personalized medicine
Post on 11-Sep-2021
3 Views
Preview:
TRANSCRIPT
1
Next Generation Tools Enabling Personalized Medicine
Caliper Owners Group, May 17, 2011
2
Biologics & Vaccines:
Targeted Small Molecules
Stem CellsBiomarkers
Genome Sequencing:
Diagnostics Therapeutics
Imaging & Pathology
Disruptive Technologies Enabling Personalized Medicine More From Less, Faster and Better™
3
Triple Crown Focus
Innovation
CultureCollaboration
RevolutionizingMedicine
• Integration• Inspiration• Boldness
• Clinical Data• Technology• Business
• Patient Centric • Therapeutics• Diagnostics
4
Dennis Ausiello, MD
Chief of Medicine at Massachusetts General Hospital Chief Scientific Officer, Partners Healthcare System Jackson Professor of Clinical Medicine at Harvard Medical School Member of Board of Directors of Pfizer, Broad Institute and TARIS SAB member: Entra, Promedior, Pulmatrix, BIND Biosciences, Proventys Undergraduate degree from Harvard College and medical degree from
the University of Pennsylvania. Dr. Ausiello was elected to the Institute of Medicine of the National
Academy of Science in 1999 and the American Academy of Arts and Sciences in 2003.
He has made a substantial contribution to knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters, and textbooks and currently serves as the co-editor of Cecil's Textbook of Medicine, now in its 23rd edition.
“The Practice of Medicine in the 21st Century”
5
Next Generation Tools Enabling Personalized Medicine
Kevin HrusovskyPresident & CEO
Caliper Owners Group, May 17, 2011
6
State of Healthcare
Triple Crown Focus
Next Generation Tools Enabling Personalized Medicine
Innovation
CultureCollaboration
RevolutionizingMedicine
7
State of Healthcare
8
Lyman & Hirsch (2010), Personalized Medicine, pp223Life Expectancy is Slowing
50% decrease in infectious disease 30% decrease in infant mortality 40% decrease in smoking 30% decrease in premature cardiovascular deaths
Extending life has become more difficult Heart / Cancer account for 50% of deaths First time in two centuries, children‟s life
expectancy is shorter than parents – obesity Five year decline is projected
9
37% increase in obesity since 2000; 2/3 now overweight
Costs doubled to $150B since 2000 (10% of costs)
Costs projected to be $400B by 2020
Linked diseases: Diabetes, heart, kidney, cancer
Reverse correlation w/ per capita energy consumption
(NEJM, 2005; AHRQ, 2006; CBO, 2008; CDC, 2009)
Obesity Reduces Life Spans & Natural Resources
+
+=
10
Increasing for most every nation 15% of GDP and increasing
Quadrupled since 1980, but life spans have only increased by 3-4 years
Extending life significantly increases costs 65+ year olds spend 4x more per year
than under 65 5% consume 50% of medical care
Historical Increase in Healthcare Costs
Lyman & Hirsch (2010), Personalized Medicine, pp223
11
(83 failures)
Source: Arrowsmith. Nat. Rev. Drug Disc. v.10, p.1 (Feb 2011); Arrowsmith. Nat. Rev. Drug Disc. v.10, p.1 (May 2011)
High Failure Rate Pushes Up Cost of Health Care
INCREASED FAILURE RATE IN RECENT YEARS: PII failure rate increased to 82% and PIII to 50%
IMPROVE CLINICAL SUCCESS RATES THROUGH: Robust science and biomarker stratification earlier Clinically relevant tools and models
(108 failures)
12
Need for Personalized Medicine; $1 Trillion Wasted Annually
“If it were not for the great variability among individuals, medicine might well have been a science and not an art.”
Sir William Osler (1949-1919)
13
Cancer Needs Biomarkers and a Precision ApproachDrug Discovery Today, 2009
Top 15 Selling Oncology Drugs Generated $27B w/ 35% response
65% non response = $18B waste Toxicity + = $20B
Biomarkers Identify which patients benefit
Targeted therapies to „right” patients
HER2 test for HerceptinKRAS test for Erbitux
80% response rate
14
Drug Therapeutic Area Biomarker(s) Label Section
Atorvastatin Metabolic & Endocrinology LDL receptor Indications & Usage
Cetuximab Oncology EGFR, KRAS Indications & Usage
Dapsone Dermatology & Dental G6PD Indications & Usage
Dasatinib Oncology Philadelphia chromosome Indications & Usage
Imatinib Oncology C-Kit, FIP1L1-PDGFRa fusion, Philadelphiachromosome, PDGFR gene rearrangement
Indications & Usage
Lapatinib Oncology Her2/neu Indications & Usage
Maraviroc CCR5 CCR5 Indications & Usage
Nilotinib Oncology Philadelphia chromosome Indications & Usage
Panitumumab Oncology EGFR, KRAS Indications & Usage
Sodium Phenylacetate & Sodium Benzoate
Gastroenterology NAGS; CPS; ASS, OTC, ASL; ARG Indications & Usage
Sodium Phenylbutyrate Gastroenterology NAGS; CPS; ASS, OTC, ASL; ARG Indications & Usage
Tamoxifen Oncology ER Indications & Usage
Tositumomab Oncology CD20 antigen Indications & Usage
Trastuzumab Oncology Her2/neu Indications & Usage
Biomarkers and Companion DiagnosticsFDA REQUIRES CDx for 14 drugs (9 Oncology); RECOMMENDS CDx for 56 approved drugs
Source: FDA Table of Pharmacogenomic Biomarkers in Drug Labels (updated 1/13/2011)
$5B
$2B
$4B
15
Biomarkers – Enabling Discovery to Therapy in Record Time Reducing drug development costs by reducing size and time of clinical trials
Gerber & Minna (2010) Cancer Cell, v.18, pp. 548-551
3 years
16
Roche and Plexxikon are developing a companion diagnostic for PLX4032.“We are anticipating that we will be able to launch not only with the drug, but the diagnostic test at the same time.”
• Plexxikon / Roche: 81% metastatic melanoma patients with a BRAF (V600E ) activating mutation responded to treatment with PLX4032, a highly selective kinase inhibitor.
“These results represent a major breakthrough and provide proof that the treatment of metastatic melanoma can be individualized for a substantial percentage of patients.”
NEJM Editorial, August 26, 2010
“We have never seen an 80% response rate in melanoma, or in any other solid tumor, for that matter, so this is remarkable.”
Paul Chapman, M.D., Memorial Sloan-Kettering Cancer Center
Source: Flaherty et al., NEJM, v. 363, pp. 809-819
Melanoma – “BRAF Inhibitor and V600E Companion Diagnostic”
17
Genomics – From “Project” to Industry in One Decade Societal Impact of the Human Genome Project
According to American Medical Association…MEDICAL IMPACT – Current and Future “More powerful medicines” Better, safer drugs and vaccines the first time More accurate drug dosage
An unexpected benefit…Economic impactINVESTMENT: $6B spent by federal government) over 13 years
RETURN ON INVESTMENT (1988 to 2010): Economic impact of $800B, personal income of $250B, 3.8M job-years of employment ROI (for federal government and tax payers) = 141 In 2010, genomics-enabled industry generated $6B+ in taxes
Economic Impact of the Human Genome Project . Battelle Technology Partnership Practice (May 2011)
18
Life Expectancy Calculator
.
Country 100 yrs+ Per 100,000China 17,800 1.3Canada 3795 11.5UK 9330 15France 14,994 25Japan 36,376 28USA 95,548 31
"If you live to the age of a hundred you have it made because very few people die past the age of a hundred.”George Burns, 1896-1996
Ruth Frith, 100Shot-put gold medalist
Buster Martin, 101Marathoner, Life Enthusiast
Jaring Timmerman, 100World record for backstroke
Eemeli Vaynyrean, 100Inventor‟s gold medal
Centenarians and Super Centenarians
19
Cost of Extending Life Spans with Today‟s Medicine
Extending life from 77 to 84 years would double medical costs
$Bill
ions
Significantly ramp healthcare costs
65+ year olds spend 4x more per
person than under 65
5% of population consume 50% of
medical care
20
$400k Total Consumption Yields:- 77 year average lifespan- Additional year = $75k
~~
$2.5M
Colorectal Cancer:- Today: $250,000 adds 24 months- 1996: $500 adds 11 months
Extending Life Using Today‟s Tools is Prohibitive
21
Expand life from 77 to 100 years- Technology & Preventive Approaches
~~
$2.5M
A Revolution in Medicine is Needed to Extend Life Economically
22
Triple Crown Focus
Innovation
CultureCollaboration
RevolutionizingMedicine
• Patient Centric • Therapeutics• Diagnostics
23
2003R&D Start up• LabChip
2010Research Dx• LabChip• Imaging• Services
2011
Personalized Medicine• Biomarkers• Therapies• Diagnostics
+• Tissue• Imaging
+++- .5- .25
Caliper Strategic Transformation
Market $100M $1,000M $2,000MRevenue $20M $120M $142M Growth Declining 10% organic 15-22%G.M. 40% 52% 52%+EBITDA ($30M) $4M $4-6M
24
Biologics & Vaccines:
Targeted Small Molecules
Stem CellsBiomarkers
Genome Sequencing:
Diagnostics Therapeutics
Imaging & Pathology
Disruptive Technologies Enabling Personalized Medicine More From Less, Faster and Better™
25
In Vitro Tissue In Vivo
Preclinical
ClinicalResearch
Clinical
Existing Capability
Developing Capability
Future Capability
= $1B Market
26
+
Existing Capability
Developing Capability
Future Capability
Preclinical
ClinicalResearch
Clinical
In Vitro Tissue In Vivo
$1B Pathology
Market
= $2B Market
27
Automation
ImagingMicrofluidics
CRO Expertise / Experience
Revolutionary Technologies
Diagnostics Therapeutics
28
ImagingMicrofluidics• over 350 issued patents• prep and analytical LabChips• multiplexing and faster kinetics
CRO Expertise / Experience
Revolutionary Technologies
Diagnostics Therapeutics
Automation• high throughput, quality and low cost
29
Microfluidics – A Decade of Commercialization
Exponential Growth from 2000-2010 and Beyond
Transition from “Technology” to “Solution”
Positioned to Address Major uF Markets in Dx
Major Partnerships Underscore Market Potential
30
IsolateSample
FragmentSample
GenerateLibrary
Quant. Sample Sequence
Library Generation- Enzymatic reaction
- Purification
Extraction/PurificationDNA and/or RNA
Shear/FractionationSize select fragments
Quantification &Sample AnalysisPurity and integrity
SequencingSeq. chemistry
Zephyr GWNucleic Acid Extraction – Genomic Workstation
LabChip GXHT Bioanalyzer-like QC for DNA and RNA
Caliper Revolutionizing NGS Workflows – NGS Bundle
LabChip DS UV-Vis DNA/RNA Quantification
Sciclone NGS Walk Away Library Preparation
LabChip XTAutomated DNA Fractionation and Sizing
GW DS GX GXNGS XTXTFaster kinetic flow cells
• Enabling Throughput• Accuracy / Precision• Sample Preservation• Productivity / Quality
31
Challenge: Feed HiSeqs• 2-3 exomes/lane x 16 lanes/run = 48 exomes/run
• 1 Sciclone feeds 3-4 HiSeqs• Manual ≈ 24 samples per week per technician
• 1 Sciclone replaces 8 technicians
Benefits• Sequencer productivity; Lower cost; Increase throughput;
96 libraries 5 hours; 192 exome capture libraries per week
Methods• RNA preparation: Illumina TruSeq & NuGen• Library Prep: SOLiD, Illumina TruSeq, NEB, Nextera• Target enrichment: SureSelect & SeqCap EZ• Coming soon: Life PGM & Illumina MiSeq
Sciclone NGS
32
Molecular Diagnostics are Changing Medicine
($Billion) 2008 2011 2013 CAGRWW MDx Market1 $3.8 $6.0 $7.5 15%WW CDx Market2 $0.9 $1.6 $2.3 21%
1 Scientia Advisors, 2010.2 West LB Research; Caliper.
33
$10.5B Clinical Dx Automation Market by 2017
Pressure on clinical laboratories to increase cost-efficiency and productivity
Pressing need for robustness, efficiency and ease of use by non-experts
Abbott, Roche, Beckman, Bio-Rad, Qiagen, Siemens and Tecan
NGS Workstation (8x manual)Isolation and Library Preparation
LabChip GX (10x manual)QC: High Throughput Bioanalyzer
LabChip XT (12x manual)Fractionation and Sizing
Source: Global Industry Analysts, Inc., (GIA), April 2011
34
Caliper MDx Value Proposition
Ontario Agency for Health– Respiratory Virus Panel (RVP): > 25K tests / yr. ($1.25M)
– 2010 study: Qiagen, Luminex, Seegene (750 pts.)
Seegene / LabChip Dx RVP won Superior sensitivity, specificity, overall accuracy
30% reduction in lab tech labor vs. Luminex
Switching to Seegene RVP/LabChip Dx
35
Automation
Imaging Technology
• whole animal and tissue• LCTF/MSI capability• multiplex biomarker analysis
Microfluidics
Expertise and Experience
Revolutionary Technologies
Diagnostics Therapeutics
36
Imaging A Picture is Worth a Thousand Assays
Rapid, cost effective disease monitoring Predict drug efficacy with clinical applicability Earlier detection: single molecule imaging Accelerated pre-clinical discovery Identify biomarkers for companion Dx
0
20
40
60
80
100
120
140
0
200
400
600
800
1000
1200
1400
1600
Cu
mu
lative G
rant A
ward
s
IVIS Publications & NIH IVIS Funded Projects
Tota
l IV
ISP
ub
lica
tio
ns
0
10
20
30
40
50
60
70
80
2005 2006 2007 2008 2009 2010 2011E
TissueLicenseServiceProduct
Units Sold/YearInstalled Base
97278
120398
132530
Addressable Market: 8,000+ units in 2010
143673
154827
1761,003
190 est.1,193+
37
Revolutionary Molecular Imagers for Testing Molecules In Vivo
Rapid and cost effective approach to monitor disease progression
In depth understanding of disease in vivo
Observe functional biology real time in high throughput longitudinal experiments
Earlier detection: single cell imaging
Accelerate pre-clinical discovery
Translational and clinically practical
LuciferaseQuantum Fx- Low dose
uCT for structure co-registerwith optical for molecularFluorescent
probes
38
Novel COX-2 Probe for Cancer and Inflammation
Source: An Aspirin for Your Cancer? The Scientist (April 2011)
Cyclooxygenase-2 probe
The COX-2/PGE2 pathway plays an important role in
many types of cancer
COX-2 is highly expressed in almost every type of
tumor at the early stages of tumor formation.
COX-2 is a useful biomarker in many tumor types
39
Targeting Tumor COX-2 Expression with FluoroCoxib A Probe
FluoroCoxib A 5-ROX (control dye)
HT29-luc2COX2 (+)
HCT116-luc2COX2 (-)
FluoroCoxib A : In vivo biomarker probe with clinical translatability
40
“Technologies that Stimulate the Inquisitive Mind”
PMCC‟s vision: “The best in cancer care, accelerating discovery, translating to cures”
Also owns a Caliper “automated gene knockdown machine” in their functional genomics lab
“Elliot‟s Machine” – Peter MacCallum Cancer Center
41
Caliper Imaging Platform Overview
Lumina II: Entry level bioluminescent/
fluorescent imaging
Lumina XR: Lumina with x-ray overlay
Spectrum: Quantitative 2D
and 3D optical imaging
Kinetic: Fast, Real-time molecular imaging
Maestro 2: Fully Automated premium
fluorescence Imaging System
Maestro EX: Entry-Level
Fluorescence In Vivo Imaging
System
Quantum FX:Fast, low dose uCT
42
In Vivo Validation: Non-specific (palpation, IHC) vs. Specific (molecular, FISH)
Can only tell that a particular antigen is present. Not that the antibody was bound to that antigen
Shows location of fluorophore inside tumor.
This is critical for validation in vivo results
43
Traditional Pathology becoming “Prone To Error”
* New York Times, Prone to Error: Earliest Steps to Find Cancer, July 19th, 2010
Traditional tissue pathology in breast cancer
• 90,000 Ductal Carcinoma in situ (D.C.I.S.) cases are misdiagnosed
Multiple biomarker classification for breast cancer prognosis / treatment
• Her2 IHC status alone has 22% false positives and 9% false negatives• Estrogen Receptor / Progesterone receptor status alone – 10-20% false positive
Quantitative, structural, multiplex biomarker data can improve diagnosis
Traditional H&E
44
Signaling Node Analysis in FFPE Tissue from Lung Cancer
Conventional Color Image
Spectral signal isolation
Pattern-recognition image analysis
Multiplexed pAKT, pERK, & pS6 (plus DAPI) – Integrated Reagent Kit Capability (CST, HistoRx)
Signal Composite Image
Analyzed Image
VectraTM Per-cell multi-parameter data
Autofluorescence removed
45
Isolating Fluorescence Signals with Spectra
Nuance uses LCTF technology to acquire images at many wavelengths to better determine fluorophore/stain distribution in cells or tissue
Monochrome Color (RGB) Multispectral
420nm
490nm
720nm
46
Eliminates autofluorescence from other labels
Signal in conventional approach was 2/3 autofluorescence
‘Unmixed’ EGFR signal
Monochrome bandpass image
23.4
1.3
0.4
69.1
99.9
6.9
Signal (Cts)
membrane 23.4
nuclear 1.3
Off sample 0.4
Signal (Cts)
membrane 69.1
nuclear 99.9
Off sample 6.9Conventional
Detecting EGFR in breast tissue
Multispectral
Signal Isolation Gives Improved Accuracy and SensitivityIF signal advantages apply to FISH too
S/B: 0.7 to 1
S/B: 18 to 1
47
Enhancement of FISH Dots with Spectral Components
conventional RGB spectral composite
48
Leading Pathologists Using Caliper MSI for Multiplexed Analysis of Tissue
Principle Invest. Institution Multiplexing Enablement
Massimo Loda Dana Farber Prostate cancer stratification (PI3K pathway – pAKT, pERK, pS6, stathmin)
Kent Osborne Baylor Breast cancer stratification (multiplexed Her1/2/3)
David Rimm Yale (HistoRX founder) Breast cancer aspirate prognostic, trainable pattern recognition
Gustavo Ayala Baylor Prostate cancer, prognostic based on tumor microenvironment analysis
Jennifer Hunt Mass General Hosp. Head & neck, multiplexed FISH prognostic (HPV 16, 18, and 33)
Humphrey Gardner Novartis Breast and lung cancer, Ph1 trials (PI3K pathway –pAKT, pERK, pS6)
Andrea Richardson Harvard Med. School Breast cancer stratification (multiplexed mRNA in FFPE)
Roger McLendon Duke University Brain cancer, multiplexed IHC prognostic
Carlo Croce Ohio State Univ. Multiplexed miRNA analysis in cancer FFPE
Mike Feldman Univ. of Penn Med. School Many cancers, multiplexed analysis for tumor infiltrating lymphocyte count, transplant rejection, proliferation assessment, etc.
Ken Bloom Clarient Breast Cancer, Multiplexed FISH and CISH
49
Cancer: Uncontrolled Cell Growth
Personalized medicine
1. What is the Biology ?
2. How can we affect and modulate the biology?
3. How can we predict and affect individual specific biology?
50
Caliper‟s unique Multiplexing
assay capability
Research biomarker
Approved diagnostic
51
Need for Multiplexed TechnologiesGetting “more from less” is critical for clinical decision-making
Horn & Pao (2009) JCO, v.26, pp. 4232-4234; Bunn & Doebele (2011) JCO, v.29, pp.1-3
Optimal treatment
Simultaneous Molecular Testing
Serial Molecular Testing (Reflex approach)*Multiplexing
52
Tissue Imaging Technology – Potential impact on MDx / CDx
• Reduction of false positives and negatives
• Multiplexing provides more accurate testing from less sample, faster
• Multi spectral imaging technology enables cleaner resolution and higher multiplexing
• Pattern recognition enables automated analysis and quantification
• Alternative representation, i.e., pseudo H&E, combined FISH / IF, Quantitative ISH or IF
ALK-FISH negative specimen
ALK-FISH positive specimen
53
Why CTC Analysis is a Game-changer
Cancer detection todaySymptom based – detection often after metastasis
Typically on primary tumor, metastatic cells are different
The promise of CTC-based analysisLiquid biopsy – non-invasive and routine
Detect metastasis before symptoms
Prognostic (> 5 CTCs per 7.5 mL of blood = aggressive)
Predictive and response / resistance monitoring
$1B investment today
Research, clinical trials and companion diagnostics
54
Circulating Tumor Cells; “one / 10 million” to “one / billion”
Yu M et al. JCB 2011;192:373-382
LabChipGX/DX
Labchip XT
Nuance/ Vectra
55
Disruptive Technologies for Important Applications
Minimizes sample yield loss
Reduces PCR biases
High quality results from smaller samples
Sciclone® G3 / Zephyr® Workstation
LabChip® GX – XT – DS – Dx
Critical IP for NGS platforms
Products More from Less, Faster and Better
Distinguishes heterogeneity / morphology intact
Accelerated small animal trials
IVIS® Lumina II
IVIS® Kinetic / Spectrum
Rapid enzyme screening and profiling for small molecule discovery programs
CRO stratification studies for tox / efficacy; Enabling drug rescue platform
LabChip® GX I / EZR – DNA, RNA, Epigenetics, Kinase, Protease, etc.
Drug Rescue – Tox - Oncology
Genome Sequencing
Imaging & Pathology
Biomarkers / MDx
Biologics & Vaccines
Targeted Small Mol
Stem Cells
Dia
gnos
tics
Ther
apeu
tics
LCTF enables multispectral / multiplexing
Eliminates auto florescence
Biomarker to CDx regulatory scale up
Nuance / Vectra / CTCs
Digital pathology platforms
LabChip® Dx + Automation
Gold standard BM discovery / validation tools LabChip® GX II – Proteins - Biologics
Many quantitative tests simultaneously IVIS® Kinetic
Emerging investment area
56
Imaging TechnologyMicrofluidic Technology
CRO expertise / experience
• pharma / bio experience• Tox / efficacy / data base• MDx / CDx / Rescue
Revolutionary Technologies
Diagnostics Therapeutics
Automation and Robotics
57
Biomarker Selection
- Annotated Panel of 200+ human cancer lines (wide range; breast, GI)
- biomarkers identification (FISH,IHC…)
Pharmacology & Genetics
- Drug susceptibility/resistance & genetic/biomarkers information
- Optimum monotherapy & drug combination treatments
- In vivo efficacy, PK/PD, dosing
Patient Stratification
- Biomarker identification of disease progression, drug susceptibility and resistance for better trials
- Align Rx and CDx development
- Competitive market differentiation
Oncology Biomarkers: In vitro to In vivo to Human Program
58
Triple Crown Focus
Innovation
CultureCollaboration
RevolutionizingMedicine
• Clinical Data• Technology• Business
59
Revolutionary Themes Drive Product Line Investments
Genome Sequencing
Imaging & Pathology
Biomarkers
Biologics & Vaccines
Targeted Small Mol
Stem Cells
Dia
gnos
tics
Ther
apeu
tics
• Emerging R&D investment opportunity
60
Improving Clinical Relevance with Rapid Innovations Cycles
Bringing technology, discovery, and development closer to patients
IRB re-invention
61
Triple Crown Focus
Innovation
CultureCollaboration
RevolutionizingMedicine
• Integration• Inspiration• Boldness
62
Secretariat Movie Clip
Sham = Cancer
63
First triple crown winner in 25 years
World record at Kentucky Derby
World record at Preakness
World record at Belmont Stakes
Only non human Man of the Year
Heart 2.5x the size of most race horses
One Vision, One Team – Triple Crown
64
What excites you about working with our customers, focusing on patients and
winning the Triple Crown?
Next Generation Tools
TODAY TOMORROW
Exploring Solving Building
65
Common Greater Purpose
Improve the quality and length of life for all mankind by commercializing disruptive technologies that enable a revolution in personalized health care.
66
Mark Roskey
67
Joe Griffith
68
Will Kruka
69
Paula Cassidy
70
Nate Cosper
71
Abbie Esterman
72
Abdel Bensaid
73
Anna Christensen
35 feet in the air, showing a group of eager sailors how to climb a mast……
74
Arthur Weissman (Mad Scientist)
“If only I had CDAS test this in Toxcast before I drank it!”
75
Bob Gardner
76
Chris Maki
77
Christian Lehmann
78
Cliff Hoytt
79
Darren Lee
Saving 1 Life
80
Hao Chen
81
Josh Molho
82
Mike Marlowe
83
Olga Campa
84
Peter Kuemmel
85
Philippe Mourere
86
Rick Ekstrom
87
Stephane Mouradian
88
Tommy Takanose
89
Wayne Lee
90
91
92
Stakeholder Input
Kathryn Tunstall Caliper BOD
Bob Burt Pfizer BOD
Ross Muken Deutsche Bank
93
Patient as Partner: John & JP Hussman• Ph.D. in Economics from Stanford
• Manages $8B hedge fund; Beat S&P 500 past decade
• JP, his17 year old son is autistic
• Hussman funded U Miami Institute of Human Genetics
• Spends all his free time studying genetics
• Used quantitative investment algorithms to analyze genes
• Published a paper linking genes to autism
Hussman's map of autism-related proteins
94
Caliper Stock up 400% in past two years
CALP
S&P 500
95
Open our Minds and Learn from OthersSteal Shamelessly Best Practices• Secretariat• Invictus• Coach Carter• Remember the Titans• Apollo 13• Rudy
Long Life Resources• http://www.livingto100.com/• http://www.realage.com• http://www.healthstatus.com/• http://www.personalgenomes.org/• http://www.webmd.com/• http://familyhealth.com/
Innovation Reading List & Resources
96
Willard ScottRick‟s Mom, Eva Bernal 104 years!Passed in January 2009
In Loving Memory
My Mom, Eileen Hrusovsky 81 years! BUCKEYE Grandma
Passed in July‟07In Loving Memory
Randy Pausch
97
Thank You!Acknowledgements:
Caliper Customers and Collaborators
Caliper Team:Irene Rombel, Ph.D., Mark Roskey, Ph.D., Nate Cosper, Ph.D., Isaac Meek, Seth Cohen, Ph.D., Anna Christensen, Ph.D., Darren Lee, Cliff Hoyt, Dan Rippy, Jeremy Lambert, Philippe Mourere, Rick Bunch, Andrew Barry, Kevin Francis, Ph.D., Denise DiRenzo, Gloria Martel, Julie McNiff, Ross Nakatsuji, Julie Coughlan, Diane Kosheff and Cathy Portanova
98
Secretariat Movie Clip
Sham = Cancer
99
One Vision One Team – Triple Crown
We have an unprecedented opportunity to impact patients
We are responsible for our mindset, belief system and unconquerable spirit
We must be masters of our fate to unleash this “Tremendous Machine”
What are the ingredients for Greatness?
- Inspire yourself and the great team around you
- Work together to build and use this tremendous machine to benefit patients
- Never Ever give in to anything but progress. Will our way forward.
- Make this our personal destiny, make this our personal moment
We can do it! We will do it! Our future starts right now and is in your capable hands…
100
Stephan Schuster, PhD
Professor of Biochemistry and Molecular Biology, Pennsylvania State University Studied chemistry at the University Munich and Konstanz (Germany) and
biochemistry at the Max-Planck-Institute for Biochemistry in Germany Postdoctoral studies at the California Institute of Technology, Pasadena, USA
His research group currently studies use of high-throughput sequencing in several areas of biology, including metagenomics, evolutionary biology and ancient
Co-Leader, Southern African Genome Project Project Leader, Wooly Mammoth Genome Project
“African Genomics: Charting Human Diversity”
top related